Yarrow Bioscience (YARW) EBITDA (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly EBITDA came in at -$3.8 million in Q1 2026, up 58.51% YoY from -$2.4 million in Q1 2025, and up 49.4% on a QoQ basis from -$7.5 million in Q2 2025.
Yarrow Bioscience (YARW) EBITDA (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of EBITDA data on file, last reported at -$3.8 million in Q1 2026.
- Quarterly EBITDA rose 58.51% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.3 million (up 26.68% YoY) and the FY2025 annual result came in at -$29.7 million, up 31.83% from the prior year.
- EBITDA rose to -$3.8 million in Q1 2026, from -$7.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$3.8 million in Q1 2026 to a low of -$13.1 million in Q3 2024.
- A 5-year average of -$8.5 million and a median of -$8.3 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA tumbled 109.99% — and 2026, when it surged 58.51%.
- Tracing YARW's EBITDA over 5 years: stood at -$8.0 million in 2022, then advanced by 14.43% to -$6.8 million in 2023, then tumbled by 86.91% to -$12.8 million in 2024, then jumped by 40.94% to -$7.5 million in 2025, then surged by 49.4% to -$3.8 million in 2026.
- The last three EBITDA figures came in at -$3.8 million (Q1 2026), -$7.5 million (Q2 2025), and -$9.2 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | -3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.10 Mn |
| Mar 31, 2026 | -3.82 Mn |
| Jun 30, 2025 | -7.54 Mn |
| Mar 31, 2025 | -9.20 Mn |
| Dec 31, 2024 | -12.77 Mn |
| Sep 30, 2024 | -13.09 Mn |
| Jun 30, 2024 | -10.40 Mn |
| Mar 31, 2024 | -7.38 Mn |
| Dec 31, 2023 | -6.83 Mn |
| Sep 30, 2023 | -6.23 Mn |
| Jun 30, 2023 | -10.32 Mn |
| Mar 31, 2023 | -5.88 Mn |
| Dec 31, 2022 | -7.98 Mn |
| Sep 30, 2022 | -9.33 Mn |
| Jun 30, 2022 | -8.29 Mn |
| Mar 31, 2022 | -8.69 Mn |
| Dec 31, 2021 | -8.85 Mn |
| Sep 30, 2021 | -10.77 Mn |
| Jun 30, 2021 | -9.54 Mn |
| Mar 31, 2021 | -9.76 Mn |